Zymeworks Announces Preliminary Results From Phase 1 Study Evaluating ZW191, ADC Targeting Folate Receptor-Alpha, At AACR-NCI-EORTC Conference

Author: Benzinga Newsdesk | October 23, 2025 11:32am

• Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer
• 64% overall response rate in gynecological cancers at doses ≥6.4mg/kg
• Responses observed at all doses evaluated at 3.2mg/kg and above demonstrating wide therapeutic index of Zymeworks' novel antibody-drug conjugate platform
• Dose optimization of ZW191 in ovarian cancer to initiate in 4Q-2025
• Investor and analyst call to be held today at 3:30 pm Eastern Time (ET)

VANCOUVER, British Columbia, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced preliminary results from a Phase 1 study evaluating ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-alpha (FR⍺), at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, being held October 22-26, 2025, in Boston, MA.

Posted In: ZYME